<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5177">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03039543</url>
  </required_header>
  <id_info>
    <org_study_id>B-1701-378-006</org_study_id>
    <nct_id>NCT03039543</nct_id>
  </id_info>
  <brief_title>Neuromuscular Blockade During Transurethral Resection of Bladder Cancer</brief_title>
  <official_title>The Effect of Neuromuscular Blockade During Transurethral Resection of Bladder Cancer on Surgical Condition and Recovery Profiles : A Prospective, Randomized and Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MSD Korea Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transurethral resection of the bladder tumor (TURB) for bladder tumor excision is the
      mainstream treatment. However, the beneficial effects of sugammadex after general anesthesia
      for TURB have not been thoroughly evaluated. Investigators hypothesized that deep NMB and
      the use of sugammadex as a reversal agent may be associated with better endoscopic surgical
      condition and recovery profile compared with moderate NMB during TURB.

      This study was designed to compare patients with deep neuromuscular blockade (NMB) with
      moderate NMB during transurethral resection of the bladder tumor (TURB) in terms of surgical
      condition and postoperative recovery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 15, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Participant, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surgical condition</measure>
    <time_frame>Right after the operation</time_frame>
    <description>the incidence of excellent surgical condition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative residual curarization</measure>
    <time_frame>PACU (postoperative 1hour)</time_frame>
    <description>Incidence of Postoperative residual curarization (PORC, TOF ratio &lt; 0.9 )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery(PACU discharge) time</measure>
    <time_frame>PACU (postoperative1hour)</time_frame>
    <description>time needed to reach a modified Aldrete score of 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the incidence of desaturation</measure>
    <time_frame>PACU (postoperative 1hour)</time_frame>
    <description>saturation less than 90%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other postoperative adverse events</measure>
    <time_frame>PACU (postoperative 1hour)</time_frame>
    <description>Pain, postoperative nausea and vomiting, dry mouth, Postoperative bladder discomfort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients satisfaction score</measure>
    <time_frame>PACU (postoperative1hour)</time_frame>
    <description>Patients satisfaction score for postoperative recovery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>moderate neuromuscular blockade</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During operation, intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2). Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>deep neuromuscular blockade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During operation, intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade. Patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <description>Intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2) neuromuscular blockade for patients with moderate neuromuscular blockade whereas intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade for patients with deep neuromuscular blockade.</description>
    <arm_group_label>moderate neuromuscular blockade</arm_group_label>
    <arm_group_label>deep neuromuscular blockade</arm_group_label>
    <other_name>Esmeron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2 and patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.</description>
    <arm_group_label>moderate neuromuscular blockade</arm_group_label>
    <arm_group_label>deep neuromuscular blockade</arm_group_label>
    <other_name>Bridion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged more than 18 years

          -  American Society of Anesthesiologists (ASA) physical status I and II

          -  scheduled to undergo elective Transurethral resection of the bladder tumor (TURB)

        Exclusion Criteria:

          -  history of neuromuscular, renal, or hepatic disease

          -  a body mass index (BMI) of &lt; 18.5 or &gt; C 30.0 kg/m2

          -  treatment with drugs known to interfere with neuromuscular function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junghee Ryu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junghee Ryu, MD, PhD</last_name>
    <phone>82-31-787-7497</phone>
    <email>jinaryu74@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>YeJi Lee, MD</last_name>
    <phone>82-31-787-7509</phone>
    <email>ladydaisy82@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Koo BW, Oh AY, Seo KS, Han JW, Han HS, Yoon YS. Randomized Clinical Trial of Moderate Versus Deep Neuromuscular Block for Low-Pressure Pneumoperitoneum During Laparoscopic Cholecystectomy. World J Surg. 2016 Dec;40(12):2898-2903.</citation>
    <PMID>27405749</PMID>
  </results_reference>
  <results_reference>
    <citation>Naguib M, Kopman AF, Ensor JE. Neuromuscular monitoring and postoperative residual curarisation: a meta-analysis. Br J Anaesth. 2007 Mar;98(3):302-16. Review.</citation>
    <PMID>17307778</PMID>
  </results_reference>
  <results_reference>
    <citation>Martini CH, Boon M, Bevers RF, Aarts LP, Dahan A. Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. Br J Anaesth. 2014 Mar;112(3):498-505. doi: 10.1093/bja/aet377. Epub 2013 Nov 15.</citation>
    <PMID>24240315</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 31, 2017</lastchanged_date>
  <firstreceived_date>January 25, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Junghee Ryu</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
